Following the completion of pre-clinical and clinical trials, BKM120 demonstrated strong inhibitory action on AKT, leading to cytotoxic and anti-proliferative effects in both hematological malignancies and solid tumors [44,45,46,47]. The gene discussed is AKT1; the disease is hematologic disorder.